CDC surveillance data show clinical Candida auris cases climbed from 2,882 in 2022 to 6,197 in 2024—more than doubling in two years—prompting an urgent antimicrobial-resistance warning. The rise is concentrated in older patients and in healthcare settings where the fungus persists on surfaces and spreads via colonized individuals and contaminated environments. The report also flags that expanded screening and changes in testing practices may partially contribute to higher counts, while noting the true burden may still be underestimated. Multi-center data described C. auris detection on gloves and/or gowns during a substantial share of care interactions. For hospitals and developers of diagnostics and therapeutics, the operational challenge is clear: faster detection, effective infection-control strategies, and robust antifungal options are increasingly urgent as spread accelerates.